Expansion across three areas: small-molecule drugs, cancer-specific peptide vaccines and antibody drugs
First written in FY2016. 18 of 25 entries say "Restated". Latest entry: 2026-05-08.
1 other company's latest entry also says "Cited as achieved".
- 2026-05-08Cited as achievedRevision of earnings forecasts
「With respect to profit, mainly due to the recognition of research and development expenses from the continued basic research on drug candidates and drug discovery research, as well as research and development expenses associated with progress in clinical development in the three areas of small-molecule drugs, cancer peptide vaccines and antibody drugs, operating profit and ordinary profit each recorded wider losses.」
The recognition of research and development expenses associated with progress in clinical development in the three areas of small-molecule drugs, cancer peptide vaccines and antibody drugs was cited as a factor behind the difference in performance. - FY2026-H1RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer peptide vaccines and antibody drugs, with the aim of clinical application」
Drug discovery research continues across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs. - FY2025RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer peptide vaccines and antibody drugs, with the aim of clinical application」
Drug discovery research continues across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs. - FY2024-Q3AdvancedAnnual report
「The research and development project titled "Formulation studies for developing a treatment for treatment-resistant, intractable breast cancer using tumor suppressor activation" has been selected for the Innovative Cancer Medical Practical Application Research Project conducted by the Japan Agency for Medical Research and Development (AMED). The project representative is Professor Katagiri Toyomasa (片桐豊雅), Director of the Institute of Biomedical Sciences at the National Institutes of Biomedical Innovation, Health and Nutrition and concurrently a professor at the Institute of Advanced Medical Sciences, Tokushima University.」
In drug discovery research, a research and development project was selected for AMED's Innovative Cancer Medical Practical Application Research Project, progressing to joint research with Tokushima University, manufacturing of investigational drugs, and efforts to identify development partners and pursue out-licensing. - FY2024-Q1AdvancedAnnual report
「As we identified within our compound library compounds with activity that potently and selectively inhibits kinases considered potentially promising therapeutic targets for organ fibrosis, we are conducting research with the goal of out-licensing them. As of the filing date of this document, we have also entered into a joint research agreement with the National Institutes of Biomedical Innovation, Health and Nutrition.」
Regarding research on compounds inhibiting kinases that could serve as therapeutic targets for organ fibrosis, the continuation of research aimed at out-licensing them and the execution of a joint research agreement with the National Institutes of Biomedical Innovation, Health and Nutrition have been specified. - FY2023AdvancedAnnual report
「As of the filing date of this document, evaluation has been completed through the second stage, and research is progressing smoothly as initially planned.」
For compounds inhibiting kinases that could serve as therapeutic targets for organ fibrosis, the second of the three evaluation stages, enzyme, cell and animal-model evaluations, has been completed. - FY2023-Q3RestatedAnnual report
「In addition, we are actively pursuing drug discovery research in each field, including small-molecule drugs, cancer peptide vaccines and antibody drugs, targeting these molecules」
Drug discovery research continues across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs. - FY2023-Q2AdvancedAnnual report
「As announced on 31 October 2022, we identified within our compound library compounds with activity that potently and selectively inhibits kinases considered potentially promising therapeutic targets for organ fibrosis, and began research with the goal of out-licensing them.」
As a research focus in small-molecule drugs, compounds inhibiting kinases that could serve as therapeutic targets for organ fibrosis were identified in the compound library, and research aimed at out-licensing them was initiated. - FY2023-Q1RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer peptide vaccines and antibody drugs, with the aim of clinical application」
Drug discovery research continues across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs. - FY2022-Q3RestatedAnnual report
「In addition, we are actively pursuing drug discovery research in each field, including small-molecule drugs, cancer peptide vaccines and antibody drugs, targeting these molecules」
Drug discovery research continues across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs. - FY2022-Q1RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer peptide vaccines and antibody drugs, with the aim of clinical application」
Drug discovery research continues across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs. - FY2021-Q3RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer peptide vaccines and antibody drugs, with the aim of clinical application」
Drug discovery research continues across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs. - FY2021-Q2RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer peptide vaccines and antibody drugs, with the aim of clinical application」
The policy of pursuing drug discovery research across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs, continues. - FY2021-Q1RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer peptide vaccines and antibody drugs, with the aim of clinical application」
The policy of pursuing drug discovery research across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs, continues. - FY2020-Q3RestatedAnnual report
「In addition, we are actively pursuing drug discovery research in each field, including small-molecule drugs, cancer peptide vaccines and antibody drugs, targeting these molecules, conducting multiple clinical trials based on the results of this research, and also having multiple drug candidates in preparation for clinical trials.」
Drug discovery research and clinical development continue across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs. - FY2020-Q2RestatedAnnual report
「In addition, we are actively pursuing drug discovery research in each field, including small-molecule drugs, cancer peptide vaccines and antibody drugs, targeting these molecules」
The policy of pursuing drug discovery research across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs, continues. - FY2020-Q1RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer peptide vaccines and antibody drugs, with the aim of clinical application」
The policy of pursuing drug discovery research across multiple fields, including small-molecule drugs, cancer peptide vaccines and antibody drugs, continues. - FY2018RestatedAnnual report
「Based on the results of basic research, our group is conducting drug discovery research, including small-molecule drugs, cancer-specific peptide vaccines and antibody drugs, with the aim of clinical application」
The policy of pursuing drug discovery research in each of the fields of small-molecule drugs, cancer-specific peptide vaccines and antibody drugs continues. - FY2018-Q3RestatedAnnual report
「In addition, we are actively pursuing drug discovery research in each field, including small-molecule drugs, cancer-specific peptide vaccines and antibody drugs, conducting multiple clinical trials based on the results of this research, and also having multiple drug candidates in preparation for clinical trials.」
The policy of conducting drug discovery research and clinical development in parallel across the fields of small-molecule drugs, cancer-specific peptide vaccines and antibody drugs has been reiterated. - FY2018-Q2RestatedAnnual report
「In addition, we are actively pursuing drug discovery research in each field, including small-molecule drugs, cancer-specific peptide vaccines and antibody drugs, conducting multiple clinical trials based on the results of this research, and also having multiple drug candidates in preparation for clinical trials.」
The policy of conducting drug discovery research and clinical development in parallel across the fields of small-molecule drugs, cancer-specific peptide vaccines and antibody drugs has been reiterated. - FY2017AdvancedAnnual report
「We have already identified peptide vaccines targeting a total of 43 genes associated with colorectal, gastric, lung, bladder, kidney, pancreatic and liver cancers, among others, and are also screening additional epitope peptides corresponding to various HLA types, including A*11:01, A*33:03, A*01:01 and A*03:01.」
For peptide vaccines, the target genes have been specified in detail as 43 genes in total, and additional screening of epitopes corresponding to multiple HLA types is under way. - FY2017-Q3RestatedAnnual report
「In addition, we are actively pursuing drug discovery research in each field, including small-molecule drugs, cancer-specific peptide vaccines and antibody drugs, conducting multiple clinical trials based on the results of this research, and also having multiple drug candidates in preparation for clinical trials.」
The policy of conducting drug discovery research and clinical development in parallel across the three fields of small-molecule drugs, cancer-specific peptide vaccines and antibody drugs has been reiterated. - FY2017-Q2RestatedAnnual report
「In addition, we are actively pursuing drug discovery research in each field, including small-molecule drugs, cancer-specific peptide vaccines and antibody drugs, conducting multiple clinical trials based on the results of this research, and also having multiple drug candidates in preparation for clinical trials.」
The policy of conducting research and clinical development in the three drug-discovery areas in parallel continues. - FY2017-Q1RestatedAnnual report
「We are actively pursuing drug-discovery research in areas including small-molecule drugs, cancer-specific peptide vaccines and antibody drugs, conducting multiple clinical trials based on the results of this research, and holding multiple drug candidates in preparation for clinical trials.」
The policy of conducting research and clinical development in the three drug-discovery areas in parallel continues. - FY2016First statedAnnual report
「We are strategically advancing research and development in three areas—small-molecule drugs, cancer-specific peptide vaccines and antibody drugs—and have begun efforts toward personalized cancer medicine.」
A business strategy pursuing multiple drug-discovery modalities in parallel.